Trial Profile

The Phase 2 "switch-over" trial evaluating OMS906 in patients demonstrating an unsatisfactory response to treatment with the C5 inhibitor ravulizumab

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 26 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

24 Oct 2024 According to an Omeros Corporation media release, the company has recently held productive meetings with regulatory authorities - an end-of-phase 2 meeting with FDA and a scientific advice meeting in Europe., clearing its path to initiate phase 3 studies for zaltenibart in PNH later in Q4 2024.
09 May 2024 According to an Omeros Corporation media release, Interim Results from this study has been selected for podium presentation at the 2024 European Hematology Association (EHA) Hybrid Congress, June 13-16, 2024, in Madrid, Spain.
09 Nov 2023 According to an Omeros Corporation media release, reporting of data is expected later this year or early 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com